**IN THE CLAIMS:**

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Currently Amended) A composition comprising a coagulation factor IXa ~~FIXa~~ and a composition comprising a coagulation factor VIII ~~FVIII~~ for simultaneous, simultaneous separate or sequential use in the treatment of haemophilia A or haemophilia B in a subject ~~which~~ who does not present with anti-FVIII antibodies.

2. (Currently Amended) A method of using a coagulation factor IXa and a coagulation factor VIII ~~FIXa and FVIII~~ in the preparation of a composition according to claim 1 for the treatment of haemophilia A or haemophilia B in a subject which does not present with anti-coagulation factor VIII ~~anti-FVIII~~ antibodies wherein the method comprises admixing coagulation factors IXa and VIII.

3. (Original) A composition comprising FIXa according to claim 1, which further comprises phospholipid.

4. (Original) A method of using FIXa in the manufacture of a composition comprising FVIII for the treatment of haemophilia A or haemophilia B, wherein the presence of FIXa allows the concentration of FVIII in the composition to be reduced in comparison to a composition which does not comprise FIXa.

5. (Currently Amended) The method according to claim 4, wherein the composition is administered to a subject ~~which~~ who does not present with anti-FVIII antibodies.

6. (Original) The method according to claim 4, wherein the FVIII and FIXa reagents are produced using recombinant DNA technology.

7. (Original) The method according to claim 4, wherein the composition further comprises phospholipid.

8. (Original) The method according to claim 4, wherein the composition is formulated to provide FVIII to a subject at a dosage of between 2 and 10 IU/kg.

9. (Withdrawn) A method for treating a subject suffering from haemophilia A or haemophilia B, comprising administering to a subject in need thereof a composition comprising FIXa and FVIII, wherein said subject does not present with anti-FVIII antibodies or wherein said composition comprises FVIII in an amount lower than that required for treatment of said subject with a composition lacking FIXa.

10. (Withdrawn) The method according to claim 9, wherein said composition further comprises phospholipid.

11. (Withdrawn) The method according to claim 9, wherein the composition comprises recombinant FIXa and recombinant FVIII.

12. (Withdrawn) The method according to claim 9, wherein the composition is formulated to provide FVIII to a subject at a dosage of between 2 and 10 IU/kg.

13. (Original) A method for potentiating FVIII comprising the step of mixing together Factor FVIII and FIXa into a composition.

14. (Original) The method according to claim 13, wherein said composition further comprises phospholipid.

15. (Original) The method according to claim 13, wherein the composition comprises recombinant FIXa and recombinant FVIII.

16. (Withdrawn) A method for reducing the immunogenicity of FVIII in a composition comprising FVIII in a subject, comprising administering FVIII together with FIXa to the subject.

17. (Withdrawn) A method of using FIXa and FVIII in the preparation of a composition for the treatment of haemophilia, wherein the FVIII in said composition has reduced immunogenicity as a result of the presence of FIXa.